Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial ...
Market Growth : From USD 695.99 million in 2022 to USD 1.6 billion by 2032 at a CAGR of 8.4% . Energy Efficiency : A primary market driver, supported by stringent regulatory measures on HVAC system ...
Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...
Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic ...